A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease "ANITA"
Latest Information Update: 25 Jul 2022
Price :
$35 *
At a glance
- Drugs Nintedanib (Primary) ; Ifosfamide
- Indications Chondrosarcoma; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Lipoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms ANITA
- 19 Nov 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 29 May 2021 Status changed from active, no longer recruiting to discontinued, according to Results published in the European Journal of Cancer.
- 29 May 2021 Primary endpoint (progression-free survival (PFS)) has not been met, according to Results published in the European Journal of Cancer.